Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
September 18, 2013
Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist
Harvey Wong, Stephen E Gould, Nageshwar Budha, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
July 31, 2012
Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis
Harvey Wong, Nageshwar R Budha, Kristina West, et al.
Molecular Cancer Therapeutics
|
March 5, 2016
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A Punnoose, Joel D Leverson, Franklin Peale, et al.
The New England Journal of Medicine
|
September 4, 2009
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma
Daniel D Von Hoff, Patricia M LoRusso, Charles M Rudin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2020
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors
Sara M Tolaney, Khanh T Do, Joseph P Eder, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
April 11, 2012
Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials
Rebecca J Brais, Susan E Davies, Maria O'Donovan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2016
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
J F Liu, K N Moore, M J Birrer, et al.
JAMA Oncology
|
April 7, 2022
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial
Daniel M Halperin, Suyu Liu, Arvind Dasari, et al.
Nature Communications
|
April 27, 2025
Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial
Shiao-Pei Weathers, Xiqi Li, Haifeng Zhu, et al.
Cancer Discovery
|
July 15, 2021
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
Kanwal Raghav, Suyu Liu, Michael J Overman, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
September 18, 2013
Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist
Harvey Wong, Stephen E Gould, Nageshwar Budha, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
July 31, 2012
Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis
Harvey Wong, Nageshwar R Budha, Kristina West, et al.
Molecular Cancer Therapeutics
|
March 5, 2016
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A Punnoose, Joel D Leverson, Franklin Peale, et al.
The New England Journal of Medicine
|
September 4, 2009
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma
Daniel D Von Hoff, Patricia M LoRusso, Charles M Rudin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2020
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors
Sara M Tolaney, Khanh T Do, Joseph P Eder, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
April 11, 2012
Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials
Rebecca J Brais, Susan E Davies, Maria O'Donovan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2016
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
J F Liu, K N Moore, M J Birrer, et al.
JAMA Oncology
|
April 7, 2022
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial
Daniel M Halperin, Suyu Liu, Arvind Dasari, et al.
Nature Communications
|
April 27, 2025
Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial
Shiao-Pei Weathers, Xiqi Li, Haifeng Zhu, et al.
Cancer Discovery
|
July 15, 2021
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
Kanwal Raghav, Suyu Liu, Michael J Overman, et al.
Page
of 3